Company intelligence / Profile preview

Aspen Park Pharmaceuticals

New York, New York, United Statesaspenparkpharma.com ↗

Ownership: Private
Development stage: Other

Overview

Aspen Park Pharmaceuticals had multiple clinical candidates and launched PREBOOST™ for premature ejaculation. Its delayed release tamsulosin (Tamsulosin DRS) for BPH received FDA expedited review pathway via 505(b)(2), facilitating rapid development. All subsequent development is under Veru.

Therapeutic areas: Women's HealthOncologyMen's HealthRheumatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Female Health Company/Veru (merger/acquisition)FDA (expedited pathway for Tamsulosin DRS)

Beyond the preview

Go deeper on Aspen Park Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspen Park Pharmaceuticals.